|
At a time of tension between vigorous innovation and increasing costs in health care, health care decision makers require comprehensive evidence of the value of new drugs, devices, procedures, and biologics. Policy makers and proponents of health care system reform thus routinely argue that simultaneously meeting the goals of sustained innovation, cost control, and improved quality within the health care system will require more explicit appraisal of the clinical effectiveness and comparative value of new and existing interventions. The mission of the Institute for Clinical and Economic Review (ICER) is to be the most trusted source of information to help fill this evidence gap for the benefit of all stakeholders in health and the health care system. ICER produces rigorous assessments of new medical interventions, and translates its findings into integrated ratings specifically formatted to support value-based insurance benefit designs, coverage and reimbursement policy, and patient-clinician decision support tools.
|
|